Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9539262 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(5 years from now) | |
US9629852 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(6 years from now) |
Market Authorisation Date: 12 September, 2018
Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Dosage: EMULSION;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic